Related Experiment Video
Updated: Jan 5, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
Nicolas Alcala1, Lise Mangiante1, Nolwenn Le-Stang2
1Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
Background:
Malignant Pleural Mesothelioma (MPM) is an aggressive disease related to asbestos exposure, with no effective therapeutic options.
Methods:
We undertook unsupervised analyses of RNA-sequencing data of 284 MPMs, with no assumption of discreteness. Using immunohistochemistry, we performed an orthogonal validation on a subset of 103 samples and a biological replication in an independent series of 77 samples.
Findings:
A continuum of molecular profiles explained the prognosis of the disease better than any discrete model. The immune and vascular pathways were the major sources of molecular variation, with strong differences in the expression of immune checkpoints and pro-angiogenic genes; the extrema of this continuum had specific molecular profiles: a "hot" bad-prognosis profile, with high lymphocyte infiltration and high expression of immune checkpoints and pro-angiogenic genes; a "cold" bad-prognosis profile, with low lymphocyte infiltration and high expression of pro-angiogenic genes; and a "VEGFR2+/VISTA+" better-prognosis profile, with high expression of immune checkpoint VISTA and pro-angiogenic gene VEGFR2. We validated the gene expression levels at the protein level for a subset of five selected genes belonging to the immune and vascular pathways (CD8A, PDL1, VEGFR3, VEGFR2, and VISTA), in the validation series, and replicated the molecular profiles as well as their prognostic value in the replication series.
Interpretation:
The prognosis of MPM is best explained by a continuous model, which extremes show specific expression patterns of genes involved in angiogenesis and immune response.
Insights
Malignant pleural mesothelioma (MPM) prognosis is best understood through a continuous molecular model, not discrete subtypes. This model reveals distinct gene expression patterns in angiogenesis and immune response at its extremes, impacting patient outcomes.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure.
- Current therapeutic options for MPM are limited and often ineffective.
Purpose of the Study:
- To investigate the molecular landscape of MPM using unsupervised analysis.
- To identify novel prognostic markers and therapeutic targets in MPM.
Main Methods:
- Unsupervised RNA-sequencing analysis of 284 MPM samples.
- Orthogonal validation using immunohistochemistry on 103 samples.
- Biological replication in an independent series of 77 samples.
Main Results:
- A continuous molecular model better predicted MPM prognosis than discrete subtypes.
- Immune and vascular pathways showed significant molecular variation, including immune checkpoints and pro-angiogenic genes.
- Distinct molecular profiles at the extremes of the continuum were identified: 'hot' (poor prognosis), 'cold' (poor prognosis), and 'VEGFR2+/VISTA+' (better prognosis).
- Protein-level validation of key genes (CD8A, PDL1, VEGFR3, VEGFR2, VISTA) and replication of prognostic findings were successful.
Conclusions:
- MPM prognosis is best explained by a continuous molecular model.
- Specific gene expression patterns in angiogenesis and immune response at the extremes of this continuum correlate with patient outcomes.
More Related Videos
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:17The Tumor Microenvironment
01:19Mesenchymal Stem Cells
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...